Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of medicine composition in preparation of medicine treating atherosclerosis

A technology for atherosclerosis and drug treatment, applied in the field of medicine, can solve problems such as liver and kidney damage, increased bleeding risk, etc.

Active Publication Date: 2018-03-16
岳红
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the above-mentioned drugs all have obvious adverse reactions such as liver and kidney damage or increased risk of bleeding, etc.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of medicine composition in preparation of medicine treating atherosclerosis
  • Application of medicine composition in preparation of medicine treating atherosclerosis
  • Application of medicine composition in preparation of medicine treating atherosclerosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0028] Example 1 Granules for treating atherosclerosis and its preparation

[0029]

[0030] Excipients: β-cyclodextrin, γ-cyclodextrin, microcrystalline cellulose, low-substituted hydroxypropyl cellulose, povidone K30 and water. The dosage of β-cyclodextrin is 0.6 times of the weight of sodium ferulate, the dosage of γ-cyclodextrin is 0.4 times of the weight of sodium ferulate, and the dosage of microcrystalline cellulose is 1 times of the weight of sodium ferulate. Propylene cellulose consumption is 0.17 times of sodium ferulate weight, povidone K30 consumption is 0.17 times of sodium ferulate weight.

[0031] Preparation:

[0032] Step 1: Take the prescribed amount of sodium ferulate, miltefosine, β-cyclodextrin, γ-cyclodextrin, microcrystalline cellulose, low-substituted hydroxypropyl cellulose, and povidone K30 and pass through 80-mesh sieves For subsequent use, get povidone K30 and add water to make an aqueous solution with a mass percentage concentration of 4% for ...

Embodiment 2

[0036] Example 2 Granules for treating atherosclerosis and its preparation

[0037]

[0038] Excipients: β-cyclodextrin, γ-cyclodextrin, microcrystalline cellulose, low-substituted hydroxypropyl cellulose, povidone K30 and water. The dosage of β-cyclodextrin is 0.6 times of the weight of sodium ferulate, the dosage of γ-cyclodextrin is 0.4 times of the weight of sodium ferulate, and the dosage of microcrystalline cellulose is 1 times of the weight of sodium ferulate. Propylene cellulose consumption is 0.17 times of sodium ferulate weight, povidone K30 consumption is 0.17 times of sodium ferulate weight.

[0039] Preparation:

[0040] Step 1: Take the prescribed amount of sodium ferulate, miltefosine, β-cyclodextrin, γ-cyclodextrin, microcrystalline cellulose, low-substituted hydroxypropyl cellulose, and povidone K30 and pass through 80-mesh sieves For subsequent use, get povidone K30 and add water to make an aqueous solution with a mass percentage concentration of 4% for ...

Embodiment 3

[0044] Example 3 Granules for treating atherosclerosis and its preparation

[0045]

[0046] Excipients: β-cyclodextrin, γ-cyclodextrin, microcrystalline cellulose, low-substituted hydroxypropyl cellulose, povidone K30 and water. The dosage of β-cyclodextrin is 0.6 times of the weight of sodium ferulate, the dosage of γ-cyclodextrin is 0.4 times of the weight of sodium ferulate, and the dosage of microcrystalline cellulose is 1 times of the weight of sodium ferulate. Propylene cellulose consumption is 0.17 times of sodium ferulate weight, povidone K30 consumption is 0.17 times of sodium ferulate weight.

[0047] Preparation:

[0048] Step 1: Take the prescribed amount of sodium ferulate, miltefosine, β-cyclodextrin, γ-cyclodextrin, microcrystalline cellulose, low-substituted hydroxypropyl cellulose, and povidone K30 and pass through 80-mesh sieves For subsequent use, get povidone K30 and add water to make an aqueous solution with a mass percentage concentration of 4% for su...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the field of medicines, and particularly relates to application of a medicine composition in preparation of a medicine treating atherosclerosis. The medicine composition is prepared from medical auxiliary materials acceptable in medical science, 21-32 parts by weight of sodium ferulate and 20-28 parts by weight of miltefosine, wherein the medicine composition is an oral solid agent, and the dosage of the medicine composition is 1.58-2.40mg / kg each day by miltefosine. The medicine composition containing sodium ferulate and miltefosine has good curative effect for atherosclerosis.

Description

technical field [0001] The invention belongs to the field of medicine, and in particular relates to the application of a pharmaceutical composition in the preparation of drugs for treating atherosclerosis. Background technique [0002] Atherosclerosis (AS) is the deposition of lipids in the intima and subintimal of the arterial wall of the artery and its branches, accompanied by the migration of smooth muscle cells in the middle layer to the subintimal hyperplasia, which thickens the intima and turns yellow or grayish yellow A common blood vessel disorder that looks like atherosclerotic plaque. The disease often involves the heart, brain, and kidneys, and is associated with diseases such as diabetes and hypertension. [0003] At present, it is believed that endothelial injury and lipid deposition in the arterial wall are the initiating factors of atherosclerosis. In addition, studies in recent years have also found that inflammatory factors are involved in the occurrence a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/661A61K31/192A61K9/16A61K47/69A61P9/10
CPCA61K9/1652A61K31/192A61K31/661A61K2300/00
Inventor 岳红张玉清
Owner 岳红
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com